<DOC>
	<DOCNO>NCT01993433</DOCNO>
	<brief_summary>The purpose study determine whether DRM02 safe effective treatment plaque psoriasis apply twice daily 6 week .</brief_summary>
	<brief_title>A Safety Efficacy Study DRM02 Subjects With Plaque Psoriasis</brief_title>
	<detailed_description>This double-blind , randomize , within-subject control , study enrol 20 subject plaque psoriasis design assess safety , tolerability , preliminary efficacy DRM02 . Safety assess study , adverse event , local skin response , urinalysis , serum chemistry hematology laboratory testing , physical examination vital sign . Preliminary efficacy assess Physician 's Lesion Assessment ( PLA ) Severity Psoriasis Area Severity Index ( PASI ) two plaque identify baseline visit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female 18 70 year age . Plaquetype psoriasis two lesion similar size identical score least 6 8 sum individual component Severity Psoriasis Area Severity Index ( PASI ) Target Lesion scale . Male nonpregnant , nonlactating female . Signed informed consent . Subjects extensive , and/or 'inverse ' , and/or exfoliative psoriasis . Subjects take systemic treatment psoriasis within 4 week prior baseline . Prior concomitant use topical treatment psoriasis within 10 cm target lesion within 4 week prior baseline . Use Enbrel within 4 week prior baseline . Psoralen &amp; ultraviolet A therapy ( PUVA ) use ultraviolet B ( UVB ) therapy and/or excessive prolong exposure ultraviolet light within 4 week prior baseline . Use Humira Remicade within 3 month prior baseline . Use Stelara within 6 month prior baseline . Subjects take oral retinoids psoriasis within 6 month prior baseline . Subjects poor skin condition within 5 cm target lesion . Subjects current drug alcohol abuser ; history immunodeficiency disease poor medical risk systemic disease active uncontrolled infection . Subjects unstable medical condition medical condition adequately control standard medical therapy . Subjects actively participate experimental therapy study receive experimental therapy within 30 day Subjects clinically significant laboratory value screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>